- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04802785
The Impact of Air Travel on Passenger Cognitive Functions
Studieoversikt
Status
Forhold
Intervensjon / Behandling
- Legemiddel: Citicoline
- Legemiddel: Cytochrome C6
- Legemiddel: Sodium Chloride Oral Product
- Legemiddel: Potassium Chloride Oral Product
- Legemiddel: Sodium Citrate Oral Product
- Legemiddel: Dextrose Oral Tablet, Chewable
- Legemiddel: Domperidone Oral Product
- Legemiddel: Simethicone
- Legemiddel: Acetylsalicylic acid
- Legemiddel: Magnesium hydroxide
- Legemiddel: Probiotic Formula
- Legemiddel: Melatonin 5 mg
Studietype
Registrering (Forventet)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Study participants (Volunteers) will be recruited through media, advertisements and announcements. Prior to the study, study participants will receive written and oral explanations of the study protocols, and written informed consent will be obtained from each study participant. All potential research participants will undergo medical and psychological selection. The components, stages of selection are almost the same as those of general professional selection: the first stage is professiography / psychogram, the second stage is psychodiagnostics, the third stage is assessment and forecasting, and the fourth stage is decision making. Selection will assess the ability of participants to perform complex sequential actions.
Inclusion criterion:
- Age from 22 to 30 years old;
- at least 15 years of education, including secondary education;
- understand and speak Russian (Due to the valid Russian-language questionnaire and methodology).
In addition, study participants will be asked not to limit their caffeine intake from their daily intake, but only water is allowed 4 hours before the neuropsychological testing. Participants in the study should not hmedical/medicallane in the last two weeks prior to the start of the study, nor should they consume alcohol during the study.
Exclusion criterion:
- A member taking melatonin (affects circadian rhythm);
- Participant with comorbidities that affect cognitive function and sleep (eg, stroke, TIA, concussion with loss of consciousness, hearing problems, chronic fatigue syndrome, depression, seasonal affective disorder, anorexia);
- A participant with another ongoing sleep disorder.
All participants must be free of a history of venous thrombosis, antithrombotic or anticoagulant medications and oral contraceptives and / or any other drugs that interfere with blood coagulation (i.e. warfarin, coumadin) for at least 2 months prior to study initiation, and sign a consent to refrain from taking medications that may affect coagulation, such as aspirin or non-steroidal anti-inflammatory drugs, within 3 days after the flight, unless there is a medical / medical need.
-
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: The study Group
|
Citicoline 500 mg (Vitaae®) per os
Andre navn:
Cytochrome10 mg per os
Andre navn:
Sodium Chloride (NaCl) 2.6 g. per os
Potassium Chloride 1.5 g per os
Andre navn:
Sodium Citrate 2.90 g per os
Andre navn:
Dextrose 13.5 g per os
Andre navn:
Domperidone 1 tablet per os
Andre navn:
3-4 capsules per os
Andre navn:
Acetylsalicylic acid 150 mg per os
magnesium hydroxide 30 mg per os
1 capsule per os.
Andre navn:
|
|
Aktiv komparator: Control group
Melatonin® 5 mg per os 2 hours before bedtime on the day of arrival for 3-4 days.
|
Melatonin 5 mg per os.
Andre navn:
|
|
Ingen inngripen: Explanatory group:
12 participants without any intervention.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Urine Specific Gravity
Tidsramme: 24 hours before the flight
|
Urine Specific Gravity test
|
24 hours before the flight
|
|
SpO2 level
Tidsramme: 24 hours before the flight
|
Pulse oximetry
|
24 hours before the flight
|
|
Ultrasound examination
Tidsramme: 24 hours before the flight
|
Ultrasound examination of the veins of the lower limbs
|
24 hours before the flight
|
|
The Liverpool Jet Lag questionnaire
Tidsramme: 24 hours before the flight
|
Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag
|
24 hours before the flight
|
|
Lake Louise Acute Mountain Sickness Assessment System
Tidsramme: 24 hours before the flight
|
Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points
|
24 hours before the flight
|
|
Neuropsychological tests (Trail Making Test, Wechsler Memory Scale - IV, Free recall
Tidsramme: 24 hours after the flight
|
Word, color, and color-word T-Scores of 40 or less are considered "low."
Word, color, and color-word T-Scores above 40 or are considered "normal."
In order for one score to be considered "higher" or "lower" than another, a 10 point or greater T score difference is required.
|
24 hours after the flight
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
SpO2 level
Tidsramme: 24 hours before the flight
|
Pulse oximetry
|
24 hours before the flight
|
|
The Liverpool Jet Lag questionnaire (LJLQ)
Tidsramme: 24 hours after the flight
|
Changes from normal (0 to 5) while jetlag rating was recorded on a scale from 0 = insignificant jetlag to 10 = severe jetlag
|
24 hours after the flight
|
|
Lake Louise Acute Mountain Sickness Assessment System
Tidsramme: 24 hours after the flight
|
Mild acute mountain sicknessas 3-5 points, moderate acute mountain sickness as 6-9 points, and severe acute mountain sickness as 10-12 points
|
24 hours after the flight
|
|
The Stroop Test
Tidsramme: 24 hours after the flight
|
Word, color, and color-word T-Scores of 40 or less are considered "low."
Word, color, and color-word T-Scores above 40 or are considered "normal."
In order for one score to be considered "higher" or "lower" than another, a 10 point or greater T score difference is required.
|
24 hours after the flight
|
|
Urine Specific Gravity
Tidsramme: 24 hours after the flight
|
Urine Specific Gravity test
|
24 hours after the flight
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Fysiologiske effekter av legemidler
- Nevrotransmittere agenter
- Molekylære mekanismer for farmakologisk virkning
- Sentralnervesystemdepressiva
- Autonome agenter
- Agenter fra det perifere nervesystemet
- Enzymhemmere
- Analgetika
- Sensoriske systemagenter
- Anti-inflammatoriske midler, ikke-steroide
- Analgetika, ikke-narkotisk
- Anti-inflammatoriske midler
- Antirevmatiske midler
- Fibrinolytiske midler
- Fibrinmodulerende midler
- Blodplateaggregasjonshemmere
- Syklooksygenase-hemmere
- Antipyretika
- Antiemetika
- Gastrointestinale midler
- Beskyttende agenter
- Dermatologiske midler
- Dopaminmidler
- Dopaminantagonister
- Antikoagulanter
- Antioksidanter
- Antiskummidler
- Bløtgjørende midler
- Chelaterende midler
- Sekvesteringsagenter
- Nootropiske midler
- Kalsiumchelateringsmidler
- Antacida
- Aspirin
- Melatonin
- Simetikon
- Magnesiumhydroksid
- Domperidon
- Sitronsyre
- Natriumsitrat
- Cytidin Difosfat Kolin
Andre studie-ID-numre
- 1 (Mobile Health and Wellness Program)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .